Clinical Trials Directory

Trials / Completed

CompletedNCT07269275

HLA Eplet Mismatches to Predict Long-term Kidney Transplant Outcomes

Prognostic Value of HLA Eplet Mismatches for Long-term Kidney Transplant Outcomes

Status
Completed
Phase
Study type
Observational
Enrollment
5,525 (actual)
Sponsor
Paris Translational Research Center for Organ Transplantation · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

Human leukocyte antigen (HLA) matching evaluates the degree of compatibility between donors and organ transplant recipients and assesses broad antigen differences that may influence immune responses post-transplant. A refined HLA matching method based on examining clusters of amino acids on HLA molecules, named eplets, has been recently developed. This method identifies immunogenic discrepancies that may not be apparent through traditional HLA matching. In recent years, assessment of HLA eplet mismatches has emerged as a promising strategy to improve immune risk stratification in kidney transplantation, which is crucial for kidney recipients' management and maximizing allograft longevity. Despite its potential, the prognostic value and clinical relevance of HLA eplet mismatches for predicting long-term kidney allograft failure has not been robustly demonstrated. In this study, the investigators aim to investigate whether HLA eplet mismatches may represent a relevant clinical tool for patient risk stratification and prediction of long-term allograft failure beyond standard clinical, histological and immunological parameters for monitoring in kidney transplant recipients.

Conditions

Interventions

TypeNameDescription
OTHERNo interventionNo intervention

Timeline

Start date
2023-01-01
Primary completion
2025-07-01
Completion
2025-07-01
First posted
2025-12-08
Last updated
2025-12-12

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT07269275. Inclusion in this directory is not an endorsement.